Industry News
Biotechnology Industry News
In this market, three things make…
In this market, three things make fundraising easier for a biotech: a derisked asset touting a well-defined profile and an experienced team to guide the program’s development.
After Harvard University scored a…
After Harvard University scored a recent legal victory over the Trump administration's “arbitrary and capricious" funding freeze orders, it appears the government is ready to go another route as it ramps up its confrontation with
Star Therapeutics will use the…
Star Therapeutics will use the financing to support its pipeline of bleeding disorder candidates, including phase 3 von Willebrand disease treatment VGA039.
Israeli drug developer BioLineRx…
Israeli drug developer BioLineRx is heading north to help Norwegian biotech Hemispherian develop its lead cancer asset in a joint venture, the partners announced in a Sept. 29 release.
Applied Therapeutics is providing…
Applied Therapeutics is providing an unusual non-update, announcing that the biotech is still figuring out a path for its rare disease asset with the FDA following a flurry of speculation late last week tied to
Gilead has bolted another asset…
Gilead has bolted another asset onto the virology engine that powers the company, paying Health Hope Pharma $10 million upfront for global rights to a candidate in a limited set of indications.
IO Biotech has resorted to halving…
IO Biotech has resorted to halving its workforce after the FDA knocked back its plans to seek approval for its cancer vaccine.
A phase 2b trial of Enanta…
A phase 2b trial of Enanta Pharmaceuticals’ respiratory syncytial virus drug candidate has missed its primary endpoint. But with other analyses generating signs of efficacy, the biotech made the case that the data support further
MoonLake’s stock took a…
MoonLake’s stock took a pummelling after the biotech blamed an unexpectedly high placebo response rate for its much-hyped inflammatory disease prospect missing the key goal of a phase 3 study.
Genmab is continuing to build up…
Genmab is continuing to build up its pipeline of wholly owned late-stage cancer assets, this time paying $8 billion for Netherlands-based Merus and its bispecific antibody.
Biogen has discontinued all gene…
Biogen has discontinued all gene therapy programs using adeno-associated virus capsids, shifting resources to modalities that have the highest likelihood of achieving better treatment outcomes.
Together, the two programs…
Together, the two programs represent a nine-figure investment from the HHS, Secretary Robert F. Kennedy Jr., said.
While Eli Lilly is rethinking its…
While Eli Lilly is rethinking its biotech incubator plans in Europe, the Big Pharma has gone ahead and opened its San Diego site.
U.S. biotechs are increasingly…
U.S. biotechs are increasingly reluctant to license their drugs to European partners in order to avoid becoming a target of the Trump administration, industry insiders have told Fierce Biotech.
Belén Garijo, who steered the…
Belén Garijo, who steered the German healthcare and electronics conglomerate through the COVID-19 pandemic, will step down as CEO in April 2026. Kai Beckmann, currently the firm's CEO of electronics, will succeed her as the
The National Institutes of Health…
The National Institutes of Health is continuing its mission to reduce the use of animals in drug testing by awarding $87 million in contracts to launch the Standardized Organoid Modeling (SOM) Center, the agency announced
Eli Lilly has pulled the plug on a…
Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a single patient, citing “strategic business reasons.” The study was designed to test bimagrumab, an asset Lilly acquired in its $1.9
The FDA’s rejection of Telix…
The FDA’s rejection of Telix Pharmaceuticals’ imaging agent has triggered layoffs at Heidelberg Pharma. With the regulatory setback delaying a $70 million payment, Heidelberg is reducing its workforce by 75% and narrowing its focus to
Merck & Co. is choosing to…
Merck & Co. is choosing to license one of Evaxion’s AI platform-based vaccine candidates, offering the Danish biotech up to $592 million for rights to the preclinical asset.
While the average earnout…
While the average earnout potential per biopharma deal has declined over the last six years, the mean upfront value has been on the rise since 2017.